Mean of the difference between the RV-GLS value of the expert and trainees in four consecutive groups of 25 fetal heart clips. by Chantelle M. de Vet (16535257)

Mean of the difference between the LV-GLS value of the expert and trainees in four consecutive groups of 25 fetal heart clips. by Chantelle M. de Vet (16535257)

Proteosomal and pan-caspase inhibitors differentially prevent the disruption of the epithelial cell barrier by the clinical <i>Leptospira</i> isolates. by Tetsuya Kakita (4922584)

Whole sample storing experiment: Mean FECs of day 0, day 1 and day 2 for hookworm, <i>A</i>. <i>lumbricoides</i> and <i>T</i>. <i>trichiura</i>. by Felix Bosch (10024550)

<i>M</i>. <i>leprae</i> was detected in the liver of a multibacillary patient and can decrease ApoA-I expression in HepG2 cells. by Robertha Mariana R. Lemes (8635935)

Fig 2 - by Megan Armstrong (1782073)

CONSORT diagram for prospective survey recruitment. by Megan Armstrong (1782073)

Patient characteristics by medical conditions pre-and post-prescription law. by Megan Armstrong (1782073)

Opioid medication use and patient satisfaction after hospital discharge. by Megan Armstrong (1782073)

Number of days and MMEs/kg prescribed at discharge by days to law change. by Megan Armstrong (1782073)

Stress strain curves (from a1 to f1), stress—AE count plots (from a2 to f2) and stress—cumulative AE count plots (from a3 to f3) for the sample temperatures of 20°C, 50°C, 100°C, 1... by Nazlı Tunar Özcan (14833635)

Imaging from a man in his 50s diagnosed with World Health Organization grade III oligodendroglioma. by Qing Wang (27728)

Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

“…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”

Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

“…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”

Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

“…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”

Association of polymorphic IC_50s versus wild<i>-</i>type at codon 876 in selected drugs tested. by Winnie Okore (14139712)

A Wearable Dual-Modal Patch for Rapid Pre-Hospital Diagnosis of Acute Myocardial Infarction by Kuo Yang (280921)

“…The time required for diagnosing ischemia was significantly reduced to 50 min after its onset. The patch is optimally integrated into a stamp-sized band-aid, accompanied by a smartphone app for data visualization and real-time analysis. …”

A Wearable Dual-Modal Patch for Rapid Pre-Hospital Diagnosis of Acute Myocardial Infarction by Kuo Yang (280921)

“…The time required for diagnosing ischemia was significantly reduced to 50 min after its onset. The patch is optimally integrated into a stamp-sized band-aid, accompanied by a smartphone app for data visualization and real-time analysis. …”

A Wearable Dual-Modal Patch for Rapid Pre-Hospital Diagnosis of Acute Myocardial Infarction by Kuo Yang (280921)

“…The time required for diagnosing ischemia was significantly reduced to 50 min after its onset. The patch is optimally integrated into a stamp-sized band-aid, accompanied by a smartphone app for data visualization and real-time analysis. …”

First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

“…Low-dose <b>35m</b> remarkably decreases LPS-induced IL-1β release both <i>in vitro</i> and <i>in vivo</i> by blocking the activation of NLRP3, indicating that <b>35m</b> can be a potential orally active therapeutic agent for the treatment of NLRP3-related diseases.…”